AIDS

1. ODONGPINY ELA, Otaalo B, Musaazi J, Nalugga EA, et al
   Risks and possible implications of weight gain after switch to dolutegravir- in a large Ugandan cohort of people living with HIV.
   AIDS. 2026 May 7. doi: 10.1097/QAD.0000000000004540.
   

   >> Share

   
   
2. STEPHEN ZR, Perazzolo S, Duan L, Eguchi M, et al
   A novel all-in-one injectable composed of tenofovir alafenamide-dolutegravir-lamivudine exhibits long-acting plasma and cell drug persistence for 8 weeks.
   AIDS. 2026 May 4. doi: 10.1097/QAD.0000000000004531.
   

   >> Share

   
   
3. FOSTER C, Blenkinsop A, Henderson M, Lyall H, et al
   Risk factors associated with adverse metabolic health in youth with perinatally acquired HIV living in the United Kingdom.
   AIDS. 2026 May 4. doi: 10.1097/QAD.0000000000004533.
   

   >> Share

   
   
4. ZHAO D, Sun L, Cen P, He Y, et al
   Renal outcomes with dolutegravir plus lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide in ART-naive adults with HIV.
   AIDS. 2026 May 4. doi: 10.1097/QAD.0000000000004535.
   

   >> Share

   
   

   
   HIV Med

5. TANG TH, Kwong RT, Chan P, Lam KW, et al
   Real-world clinical and laboratory changes after switching to two-drug regimen in HIV-suppressed individuals: 48 weeks and beyond.
   HIV Med. 2026 May 4. doi: 10.1111/hiv.70247.
   

   >> Share

   
   

   
   J Med Virol

6. LUO Q, Xu R, Zhang Y, Xu W, et al
   Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High-Replicative Low-Inflammatory Phase: A 48-Week Randomized Controlled Trial.
   J Med Virol. 2026;98:e70960.
   

   >> Share

   
   

   
   JAMA

7. JENG WJ, Yip TC, Lok AS
   Hepatitis B: A Review.
   JAMA. 2026 May 4. doi: 10.1001/jama.2026.6070.
   

   >> Share

   
   

Free Medical Abstracts
Privacy Policy
Sponsors
Share